3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
48
Neoplasm Metastasis
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hyperglycemia
3
Multiple Endocrine Neoplasia Type 1
2
Advanced Breast Cancer
2
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pre-menopausal Breast Cancer
1
Pancreatic Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal, Breast
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced HER2+Breast Cancer
1
Interventions
NVP-BKM120
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pre-menopausal Breast Cancer
×
Alpelisib
×
Breast
×
Clear all
NCT02058381
2020-03-09
B-YOND
Novartis
Phase 1
Completed
40 enrolled